OIPE JC10
JUL 05 2005
PATENT & TRADEMARK OFFICE

Attorney Docket No. 263.PC2
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Chen et al.

Serial No.: 10/687,373 Group No.: 1625

Filed: October 16, 2003 Examiner: Evelyn M. Huang

For: PRE-ORGANIZED TRICYCLIC INTEGRASE INHIBITOR COMPOUNDS

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT BEFORE MAILING DATE OF EITHER A FINAL ACTION OR NOTICE OF ALLOWANCE (37 CFR 1.97 (c))

TIME TRANSMITTAL OF ACCOMPANYING INFORMATION DISCLOSURE STATEMENT

1. The information disclosure statement transmitted herewith is being filed *after* three months of the filing date of this national application or the date of entry of the national stage as set forth in § 1.491 in an international application or after the mailing date of the first Office action on the merits, whichever event occurred last but *before* the mailing date of either:

(1) a final action under § 1.113 or

(2) a notice of allowance under § 1.311,

whichever occurs first.

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Robin Torres
(Type or print name of person mailing paper)

Date: June 30, 2005

Robin Torres
(Signature of person mailing paper)

CERTIFICATION OR FEE

2. Accompany this transmittal is

A. ☐ a certification as specified in 37 CFR 1.97 (e)

OR

B. ☒ the fee set forth in 37 CFR 1.17 (p) for submission of an information disclosure statement under § 1.97 (c). ($180.00).

FEE PAYMENT

3. Applicant elects the option to pay the fee set forth in 37 CFR 1.17 (p) for submission of an information disclosure statement under § 1.97 (c). ($180.00).

Fee due $ 180.00

METHOD OF PAYMENT OF FEE

4.

☐ attached is check in the sum of $ _____


☒ charge Account No. 07-1250 the sum of $ 180.00

A duplicate of this request is attached.

If any additional fees are due, please charge Account No. 07-1250 .

Reg. No.: 27,043

Gilead Sciences, Inc
333 Lakeside Drive
Foster City, CA 94404
Tel. No.: (650) 522-5546
Fax: (650) 522-5575



SIGNATURE OF ATTORNEY

Max D. Hensley
Type or print name of attorney

OIPE JC10
JUL 05 2005
PATENT & TRADEMARK OFFICE

Attorney Docket No. 263.PC2
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Chen et al.

Serial No.: 10/687,373 Group No.: 1625

Filed: October 16, 2003 Examiner: Evelyn M. Huang

For: PRE-ORGANIZED TRICYCLIC INTEGRASE INHIBITOR COMPOUNDS

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT (modified)

List of Sections Forming Part of This Information Disclosure Statement.

The following sections are being submitted for this Information Disclosure Statement:

1. [x] Preliminary Statements
2. [x] FORM PTO - 1449 (Modified)
3. [x] Copies of Listed Information Items Accompanying This Statement

Section 1. Preliminary statements

Applicants submit herewith patents, publications or other information of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose.

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 CFR 1.97 (g)), an admission that the information cited is, or is considered to be, material to patentability or that no other material information exists.

The filing of this information disclosure statement shall not be construed as an admission against interest in any manner. Notice of January 9, 1992, 1135 O.G. 13-25, at 25.

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Robin Torres
(Type or print name of person mailing paper)

Date: June 30, 2005

Robin Torres
(Signature of person mailing paper)

07/07/2005 RFEKADU1 00000055 071250 10687373
01 FC:1806 180.00 DA

JUL 0 5 2005
PATENT & TRADEMARK OFFICE

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(37 CFR 1.98(b))

ATTY DOCKET NO.: 263.PC2	SERIAL NO.: 10/687,373
APPLICANT: Chen et al.	
FILING DATE: 10/16/03	GROUP ART UNIT: 1625
EXAMINER NAME:	

Sheet 1 of 4

U.S. PATENT DOCUMENTS

Examiner initials	Cite No.	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear
		3,113,135	12-03-1963	HODEL ET AL	
		4,816,570	03-28-1989	FARQUHAR	
		4,968,788	11-06-1990	FARQUHAR	
		5,252,560	10-12-1993	MYERS ET AL	
		5,324,839	06-28-1994	Clemence et al.	
		5,538,988	07-23-1996	MARTINEZ ET AL	
		5,602,146	02-11-1997	Billhardt-Troughton et	
		5,663,159	09-02-1997	STARRETT JR. ET AL	
		5,792,756	08-11-1998	STARRETT JR. ET AL	
		5,798,340	08-25-1998	BISCHOFBERGER ET AL	
		5,854,275	12-29-1998	ROBINSON	
		6,187,907	02-13-2001	CHEN ET AL	
		6,218,402	04-17-2001	Chalmers et al.	
		6,245,806	06-12-2001	DOMBROWSKI ET AL	
		6,271,402	08-07-2001	SINGH ET AL	
		6,310,211	10-30-2001	VAILLANCOURT ET AL	
		6,312,662	11-06-2001	ERION ET AL	
		6,395,743	05-28-2002	HEIMBUCH ET AL	

FOREIGN PATENT DOCUMENTS

Examiner initials	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages Or Relevant Figures Appear	T
		WO 00/39086 A1	07-06-2000	SHIONOGI & CO., LTD		
		WO 00/75122 A1	12-14-2000	SHIONOGI & CO., LTD		
		WO 01/00578 A1	01-04-2001	MERCK & CO. INC.		
		WO 02/055079	07-18-2002	MERCK & CO. INC.		
		WO 02/30426 A1	04-18-2002	MERCK & CO. INC.		

EXAMINER DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449	ATTY DOCKET NO.: 263.PC2 SERIAL NO.: 10/687,373
U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	APPLICANT: Chen et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: 10/16/03 GROUP ART UNIT: 1625
(37 CFR 1.98(b))	EXAMINER NAME:
Sheet 2 of 4	

Examiner initials	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages Or Relevant Figures Appear	T
		WO 02/30930 A2	04-18-2002	MERCK & CO. INC.		
		WO 02/30931 A2	04-18-2002	MERCK & CO. INC.		
		WO 02/36734 A2	05-10-2002	MERCK & CO. INC.		
		WO 91/19721 A1	12-26-1991	GLAZIER, ARNOLD		
		WO 99/62513 A1	12-09-1999	MERCK & CO. INC.		
		WO 99/62520 A1	12-09-1999	MERCK & CO. INC.		

NON PATENT LITERATURE DOCUMENTS

Examiner initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium,catalog, etc.), date, page(s), volumn-issue number(s), publisher, city and/or country where published.	T
		ARTERBURN et al., "Catalytic Amination of 2-Substituted Pyridines wth Hydrazine Derivatives", 3(9):1351-1354, ORGANIC LETTERS, 2001	
		ARTICO et al, "Geometrically and Conformationally Restrainse Cinnamoyl Compounds as Inhibitors of HIV-1 Integrase: Synthesis, Biological Evaluation, and Molecular Modeling", 41:3948-3960, J MED CHEM, 1998	
		BEAUCHAMP ET AL., "Guanine, Pyrazolo[3,4-d]pyrimidine, and Triazolo[4,5-d]pyrimidine (8-Azaguanine) Phosphonate Acyclic Derivatives as Inhihibitors...", 39(4):949-956, J MED CHEM, 1996	
		BHUTA ET AL, "Analogs of Chloramphenicol: Circular Dichroism Spectra, Inhibition of Ribosomal Peptidyltransferase, and Possible Mechanism of Action", 23(12):1299-1305, J MED CHEM, 1980	
		Benzaria et al, "Synthesis, in Vitro Antiviral Evaluation, and Stability Studies of Bis(S-acyl-2-thioethyl) Ester Derivatives of 9-[2-(Phosphonometyoxy)ethyl]adenine (PMEA) as Potential PMEA Prodrugs with Improved Oral Bioavailability", 39:4958-4965, J MED CHEM, 1996	
		Bigge et al., "Exploration of N-Phosphonoalkyl-, N-Phosphonoalkenyl-, and N-(Phosphonoalkyl)phenyl-Spaced...", 35(8):1371, J MED CHEM, 1992	
		Buolamwini et al, "CoMFA and CoMSIA 3D QSAR and Docking Studies on Conformationally-Restrained Cinnamoyl HIV-1 Integrase Inhibitors: Exploration of a Binding Mode at the Active Site", 45:841-852, J MED CHEM, 2002	
		CAMPAGNE ET AL, "(1H-Benzotriazol-1-yloxy)tris(dimethylamino)phosphonium Hexafluorophosphate-and-Benzotriazol-1-yloxy)tripyrrolidinophosphonium Hexafluorophosphate-Mediated Activiation of Monophosphonate Esters: Synthesis of Mixed Phosphonate Diesters...", 60(16):5214-5223, J ORG CHEM, 1995	
		CATES et al., "Phosphorus Analogues of -Aminobutyric Acid, A New Class of Anticonvulsants", 27(5):654-659, J MED CHEM, 1984	

EXAMINER	DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 **U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE** **INFORMATION DISCLOSURE STATEMENT BY APPLICANT** (37 CFR 1.98(b))	ATTY DOCKET NO.: 263.PC2 SERIAL NO.: 10/687,373
	APPLICANT: Chen et al.
	FILING DATE: 10/16/03 GROUP ART UNIT: 1625
	EXAMINER NAME:
Sheet 3 of 4	

Examiner initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium,catalog, etc.), date, page(s), volumn-issue number(s), publisher, city and/or country where published.	T
		CHEN ET AL, "Design, Synthesis, and Biochemical Evaluation of Phosphonate and Phosphonamidate Analogs of Glutathionylspermidine as Inhibitors...", 40(23):3842-3850, J MED CHEM, 1997	
		COREY et al, "Selective Cleavage of Allyl Ethers Under Mild Conditions By Transition Metal Reagents", 38(18):3224, J ORG CHEM, 1973	
		Chen et al, "Structure-Based Design of a Novel, Potent, and Selective Inhibitor for MMP-13 Utilizing NMR Spectroscopy and Computer-Aided Molecular Design", 122:9648-9654, J AM CHEM SOC, 2000	
		Chen et al, "Anthranilate Sulfonamide Hydroxamate TACE Inhibitors, Part 1: Structure-Based Design of Novel Acetylenic P1' Groups", 12:1195-1198, BIOORG MED CHEM LETT, 2002	
		Chen et al, "Structure-Based Design of Potent Inhibitors of Scytalone Dehydratase; Displacement of a Water Molecule from the Active Site", 37:17735-17744, BIOCHEM, 1998	
		Chihab-Eddine et al, "Synthesis and reactivity of (1S)-N-(1-phenylethyl)maleimide towards nucleophiles: an application to preparation of chiral pyrroloisothiochroman and pyrrolobenzo[d]thiepine based...", 42:573-576, TET LETT, 2001	
		DAVIES ET AL, "Dinucleotide Analogues as Inhibitors of Thymidine Kinase, Thyidylate Kinase, and Ribonucleotide Reductase", 31(7):1305-1308, J MED CHEM, 1988	
		DeLombaert et al, "N-Phosphonomehtyly Dipeptides and Their Phosphonate Prodrugs, a New Generation of Neutral Endopeptidase (NEP 3.4.24.11) Inhibitors", 37:498, J MED CHEM, 1994	
		GALEOTTI ET AL, "A Straightforward Synthesis of -Amino Phosphonate Monoesters Using BroP or TPyCIU", 37(23):3997-3998, TET LETT, 1996	
		Gali et al, "Facile Ring-Opening Reactions of Phthalimides as a New Strategy to Synthesize Amid Functionalized Phosphonates, Primary Phosphines, and Bisphosphines", 65(3):676-680, J ORG CHEM, 2000	
		Goldgur et al, "Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: A platform for antiviral drug design", 96:13040-13043, PROC NATL ACAD SCI, 1999	
		Jing et al, "Potassium-Dependent Folding: A Key to Intracellular Delivery of G-Quartet Olignonucleotides as HIV Inhibitors", 41:5397-5403, BIOCHEM, 2002	
		Khamnei et al, "Neighboring Group Catalysis in the Design of Nucleotide Prodrugs", 39:4109-4115, J MED CHEM, 1996	
		LaForge et al., "Rotenone. XXVI. Synthesis of the Parent Substances of Some Characteristic Rotenone Derivatives", 55(7):3040-3048, J AM CHEM SOC, 1933	
		Lam et al., "Cyclic HIV Protease Inhibitors: Synthesis, Conformational Analysis, P2/P2' Structure-Activity Relationship, and Molecular Recognition of Cyclic Ureas", 39:3514-3525, J MED CHEM, 1996	
		MORGAN ET AL, "Structure-Based Design of an Inhibitor of the Zinc Peptidase Thermolysin", 116(8):3251-3260, J AM CHEM SOC, 1994	
		MORR ET AL, "Formation of Phostonic Acids During The Reduction of Azidonucleosidephosphonic Acids", 42:8841-8843, TET LETT, 2001	

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

FORM PTO-1449 **U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE** **INFORMATION DISCLOSURE STATEMENT BY APPLICANT** (37 CFR 1.98(b))	ATTY DOCKET NO.: 263.PC2 SERIAL NO.: 10/687,373
	APPLICANT: Chen et al.
	FILING DATE: 10/16/03 GROUP ART UNIT: 1625
	EXAMINER NAME:
Sheet 4 of 4	

Examiner initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium,catalog, etc.), date, page(s), volumn-issue number(s), publisher, city and/or country where published.	T
		MUSIOL ET AL, "On the Synthesis of Phosphonamidate Peptides", 59(21):6144-6146, J ORG CHEM, 1994	
		Matier et al, "Sulfamoyl Azides. Hydrolysis Rates and Hypotensive Activity", 15(5):538-541, J MED CHEM, 1972	
		Matsumura, "Friedel and Crafts Reaction with 8-Hydroxyquinoline"; 57:124-128, J AM CHEM SOC, 1935	
		Mattson et al., "An Improved Method for Reductive Alkylation of Amines Using Titanium (IV) Isopropoxide and Sodium Cyanoborohydride", 55(8):2552-2554, J ORG CHEM, 1990	
		Mitchell et al, "Bioreversible Protection for the Phospho Group: Bioactivation of the Di(4-acyloxybenzyl) and Mono(4-acyloxybenzyl) Phosphoesters of Methylphosphonate and Phosphonoacetate", 2345, J CHEM SOC PERKIN TRANS I, 1992	
		Ornstein et al, "Synthesis and Pharmacology of a Series of 3- and 4-(Phosphonoalkyl)pyridine- and -piperidine-2-carboxylic Acids. Potent N-Methyl-D-aspartate Receptor Antagonists", 32:827-833, J MED CHEM, 1989	
		Pais et al, "Structure Activity of 3-Aryl-1,3-diketo-Containing Compounds as HIV-1 Integrase Inhibitors", 45:3184-3194, J MED CHEM, 2002	
		Pallella et al., "Declining Morbidity and Mortality Among Patients with Advanced Human Immunodeficiency Virus Infection", 338:853-860, J MED CHEM, 1998	
		Pommier et al, "Retroviral integrase inhibitors year 2000: update and perspectives", 47:139-148, ANTIVIRAL RES, 2000	
		SADDY ET AL, "Selective Monodeprotection of Phosphonate, Phosphite, Phosphonate, and Phosphoramide Benzyl Esters", 60(9):2946-2947, J ORG CHEM, 1995	
		SASAKI et al., "Convenient Synthesis of Some Purine 8,5'-Imino Cyclonucleosides", 43(12):2320-2325, J ORG CHEM, 1978	
		Serafinowska et al., "Synthesis and in Vivo Evaluation of Prodrugs of 9-[2-(Phosphonomethoxy)ethoxy]adenine", 38:1372-1379, J MED CHEM, 1995	
		Smith et al, "A novel MyD-1 (SIRP-1) signaling pathway that inhibits LPS-induced TNF production by monocytes", 102(7):2532-2540, BLOOD, 2003	
		VAN DER LAAN ET AL, "An Approach Towards the Synthesis of Oligomers Containing a N-2-Hydroxyethyl-aminomethylphosphonate Backbone:A Novel PNA Analogue", 37(43):7857-7860, TET LETT, 1996	
		YAMAUCHI ET AL, "Synthesis of Peptides Analogs Containing(2-aminoethyl)phosphonic acid (ciliatine)", 49(7):1158-1163, J ORG CHEM, 1984	

EXAMINER DATE CONSIDERED


EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Section 3. Copies of Listed Information Items Accompanying This Statement

Legible copies of all items listed in Form PTO-1449 accompany this information statement.

Reg. No.: 27,043

Gilead Sciences, Inc
333 Lakeside Drive
Foster City, CA 94404
Tel. No.: (650) 522-5546
Fax: (650) 522-5575



SIGNATURE OF ATTORNEY

Max D. Hensley
Type or print name of attorney